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Abstract
Outbreaks involving either H5N1 or H1N1 influenza viruses (IV) have recently become an increasing threat to cause potential
pandemics. Pigs have an important role in this aspect. As reflected in the 2009 human H1N1 pandemia, they may act as a
vehicle for mixing and generating new assortments of viruses potentially pathogenic to animals and humans. Lack of
universal vaccines against the highly variable influenza virus forces scientists to continuously design vaccines a` la carte,
which is an expensive and risky practice overall when dealing with virulent strains. Therefore, we focused our efforts on
developing a broadly protective influenza vaccine based on the Informational Spectrum Method (ISM). This theoretical
prediction allows the selection of highly conserved peptide sequences from within the hemagglutinin subunit 1 protein
(HA1) from either H5 or H1 viruses which are located in the flanking region of the HA binding site and with the potential to
elicit broader immune responses than conventional vaccines. Confirming the theoretical predictions, immunization of
conventional farm pigs with the synthetic peptides induced humoral responses in every single pig. The fact that the
induced antibodies were able to recognize in vitro heterologous influenza viruses such as the pandemic H1N1 virus
(pH1N1), two swine influenza field isolates (SwH1N1 and SwH3N2) and a H5N1 highly pathogenic avian virus, confirm the
broad recognition of the antibodies induced. Unexpectedly, all pigs also showed T-cell responses that not only recognized
the specific peptides, but also the pH1N1 virus. Finally, a partial effect on the kinetics of virus clearance was observed after
the intranasal infection with the pH1N1 virus, setting forth the groundwork for the design of peptide-based vaccines against
influenza viruses. Further insights into the understanding of the mechanisms involved in the protection afforded will be
necessary to optimize future vaccine formulations.
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Introduction
In the last decades, several cases of human infection with the
highly pathogenic avian influenza virus (HPAIV) H5N1 have been
reported by the World Health Organization http://www.who.int/
influenza/human_animal_interface/avian_influenza/en/). It is a
common assumption that the pig may act as mixing vessel to
generate new reassortant influenza viruses due to the presence of
receptors for both avian and mammalian influenza viruses in the
epithelial cells of their respiratory tract [1]. A recent example of the
latter caused the first pandemia of the 21st century, starting in 2009
as a consequence of the global spread of a swine-origin influenza
virus A H1N1 (pH1N1). This was a virus that contained genes from
avian, pig and human origin [2]. Although the virus was not as
pathogenic to humans as expected, severe disease cases associated
with pH1N1 have been more recently reported in England (http://
www.who.int/influenza/surveillance_monitoring/updates/
2010_12_30_GIP_surveillance/en/). The future evolution of this or
any emergent influenza virus (IV) is uncertain. This is a distressing
matter particularly because available vaccines and therapies are
strictly restricted to phylogenetically closely related circulating
viruses. Therefore, finding universal and effective vaccines and
therapeutic measures to fight against future IV is a must for public
health.
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IV hemagglutinin (HA) is a viral surface polypeptide that
mediates both, the binding of IV to the host cell surface and the
fusion of viral and endosomal membranes [3]. HA is formed by
subunit 1 (HA1) and subunit 2 (HA2) and both the N- and C-
terminal parts of HA1 together with HA2 comprise the stalk of the
molecule [4]. Vaccines designed to elicit antibodies against the
stalk of HA are reported to confer protection against IV infection
in mice [5]. HA1, although highly variable, encodes specific and
highly conserved domains which may be involved in determining
the recognition and targeting (RTD) of influenza viruses to their
receptor as revealed by the Informational Spectrum Method (ISM)
[6]. This includes the VIN1 domain, located within the site E in
the N-terminus of HA1 [7]. In contrast with the high variability
suffered by the globular part of the HA1 molecule, which is
directly responsible for the receptor tropism, the site E remains
relatively highly conserved [8]. Thus, representing potential
targets to develop broad array of protective therapies and vaccines
against IV infection.
Due to the already mentioned recent cases related to H5N1 and
H1N1 IV subtypes, and because their potential to cause future
outbreaks among the population, we focused our efforts on
designing a vaccine capable of confering protection against both
viral subtypes. As previously reported, RTD of HA1 from different
H1N1 strains and HA1 from the recently emerged in Egypt H5N1
IV encode the same information.However,HA1 fromH3N2and all
other H5N1 viruses encode different RT information [6,7]. Thus,
aiming to increase the vaccine coverage, one HA1-peptide from the
VIN1 domain of H1N1 and three HA1-peptides from two different
H5N1 IV strains were designed and selected based on ISM.
In order to test the immunogenicity of our experimental vaccine,
we decided to immunize conventional pigs with the combination of
the synthesized peptides. Pigs allow the evaluation of the protective
efficacy of experimental vaccines against several viral strains,
including the recently pandemic H1N1 virus, pH1N1 [11].
Confirming the rationale behind their use as a pre-clinical animal
model, immunization of conventional pigs with the VIN1-peptide
cocktail allow us to demonstrate the induction of peptide-specific
antibody and T-cell responses in every single animal, independently
of their swine leukocyte antigen (SLA)-haplotype. Specific B and T-
cell responses were induced against each one of the H1 and H5-
peptides used, confirming their immunogenicity in vivo. Interesting-
ly, the elicited antibodies also recognized several heterologous
viruses in vitro, including the pH1N1, two swine influenza field
isolates (SwH1N1 and SwH3N2) and a H5N1 highly pathogenic
avian virus. This, together with the fact that the specific T-cell
responses induced were also able to recognize the inactivated
pH1N1, encouraged us to challenge all pigs with the pH1N1
influenza virus. Albeit preliminary, our results demonstrate that
VIN1-vaccination was able to confer a partial protection against
intranasal challenge with pH1N1, as demonstrated with the partial
and total viral clearance from the lung lavages in two out of four
immunized pigs. We believe that our results could contribute to the
obtainment of a broader array of protective vaccines against future
influenza outbreaks or even pandemics.
Results
VIN1 as a Synthetic Peptide-vaccine
The highly conserved VIN1 domain, located within the E site in
the N-terminus of the HA1 molecule, plays an important role in
the recognition and targeting (RT) between virus and receptor,
therefore representing an ideal target for an antibody-mediated
therapy against influenza infection [7]. Informational spectral
analysis revealed that the RT domains of HA1 from H1N1/1918,
pH1N1/2009, seasonal H1N1 and H5N1 emerged in Egypt
encode the same information despite differences in their primary
structures. Thus, based on ISM and using information available
on the properties of HA and its receptors, a single 34-mer peptide
(NF-34) from the H1N1 subtype was selected from within the
VIN1 region. NF-34 corresponds to positions 87–120 from the A/
South Carolina/1/18 (H1N1) virus (Table 1). Additionally, a
peptide (ES-34) from the VIN1 domain from the A/Egypt/0636-
NAMRU3/2007 (E; H5N1) was also selected and included in the
vaccine. In previous studies, we also showed that HA1 from H3N2
and all other H5N1 encode different RT information [6,7].
Aiming to increase the vaccine coverage, two additional peptides
(LE-35.1 and LE-35.2) were selected from the A/Hong Kong/
213/03 (HK; H5N1) IV and both peptides were added to NF-34
and ES-34. LE-35.1 and LE-35.2 differ only in positions 43 and 48
(Table 1), representing ‘‘hot spots’’ of variability within this H5N1
sequence.
Amino acid sequences from pH1N1 virus and VIN1-peptides
are given in Table 1. The identity between pH1N1 virus and NF-
34 (H1-peptide) is 92%. The similarity between all the H5-
peptides and the pH1N1 virus is less than 75% with even lower
identities, being less than 40% when comparing pH1N1 and ES-
34. There was no homology between the HK-derived peptides
(LE-35.1 and LE-35.2) and the E-derived peptide (ES-34). The
two amino acid differences between LE-35.1 and LE-35.2
represent a 95% of identity between them.
Immunogenicity of VIN1 Peptides in a Pig Model
The pig is a good model not only to study influenza
pathogenesis and therapy [9], but also for developmental
immunology [10]. Thus, to confirm the bioinformatic predictions
related to the capacity of VIN1-peptides to elicit humoral
responses, four of the influenza-seronegative pigs were immunized
three times with the VIN1-peptide mixture with two week intervals
between immunizations. Four extra-pigs (also negative for IV
antibodies) were inoculated with saline solution and remained as
negative controls during the assay. To evaluate the ability of the
VIN1-peptide cocktail to elicit antibodies, sera obtained 15 days
after each immunization were tested against the peptides. Results
obtained by ELISA showed that the immunization was efficient
since every single immunized pig produced specific antibodies
against the VIN1-peptide pool, detectable after the second
immunization (Fig. 1A). VIN1-peptides also elicited high antibody
titres against each one of the single peptides included in the
vaccine (Fig. 1B). In correlation with the high specificity shown in
the peptide-ELISA, sera from peptide-immunized pigs specifically
reacted against the purified hemagglutinin protein of H5- and H1-
subtypes, with only one serum from the V1N1 group showing
background OD values in the H1-ELISA (Fig. 1C).
Finally, we were intrigued to find that VIN1-peptides also had
the ability to induce T-cell responses. PBMC isolated from VIN1-
immunized pigs specifically secreted IFN-c in response to in vitro
stimulation with VIN1-peptide cocktail (Fig. 2). First, we noted
that VIN1-PBMC specifically secreted IFN-c two weeks after the
first immunization. Second, a homogeneous T-cell activity against
the V1N1-peptide cocktail was detected between animals after the
third immunization (Fig. 2A). And third, that all peptides were
recognized by the specific T-cell induced (Fig. 2B). These results
demonstrated that VIN1-peptides could act as productive immu-
nogens in pigs.
Broad Immune Responses Induced by HA1-peptides
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VIN1 Peptide Immunization Partially Prevent pH1N1 Virus
Replication in BAL
As previously reported, the pig can be used to evaluate the
protection of experimental pH1N1 influenza vaccines since they
are natural receptive hosts for this virus subtype [11]. Aiming to
evaluate the protective potential of our vaccine prototype, VIN1
peptide-vaccinated and control pigs were subjected to intranasal
challenge with 106 TCID50 of pH1N1 IV. The pH1N1 virus
differs in three amino acids from the H1-peptide (NF-34) used in
the vaccine (Table 1).
Intranasal infection of control pigs caused a subclinical infection
and minor hystopathological changes. Moreover, mild to moder-
ate BIP was recorded at necropsy (6 dpi), albeit virus was
recovered from BAL at this time-point (Fig. 3). These results are in
concordance with previously reported data obtained using
colostrums-deprived pigs [11]; therefore, validating the use of
seronegative conventional animals for vaccine testing. We did not
detect differences in the severity of the lesions in lungs of
vaccinated and non vaccinated animals. However, in contrast with
control pigs, 2 out of 4 VIN1-peptide vaccinated pigs showed no
or less viral RNA in their BAL (Fig. 3), which demonstrates a
partially protective effect of our experimental vaccine.
VIN1 Peptides Induce Antibodies and T-cells that
Specifically Recognize the pH1N1 Virus
In an attempt to correlate the protection provided from the
immunological outcome induced by our vaccine, sera from
immunized and control pigs were used to evaluate their capability
to in vitro recognize the pH1N1. Sera obtained before the challenge
from pigs vaccinated with VIN1-peptides, specifically detected
pH1N1 infected-MDCK cells, as shown by indirect IF (Fig. 4
panel A). As expected, sera from control animals showed no
reaction (Fig. 4 panel B); thus, demonstrating the ability of the
peptide-induced antibodies to specifically identify the virus.
Importantly, every single cell infected by pH1N1 was also
recognized by the specific NS1-monoclonal antibody (Fig. 4 panel
C) confirming the specificity of the reactions. Furthermore, sera
from 2 of the pigs immunized with VIN1-peptides showed
detectable HI activity, albeit at low titre and only those obtained
at 6 dpi (Fig. 5A). As expected, sera from the control pigs did not
show any specific response even at 6 dpi, which confirms the
efficacy of our experimental vaccine to prime for viral-specific
antibody responses. Regarding the presence of SNT antibodies, no
significant differences were observed between the animal groups,
at least at day 6pi (Fig. 5A).
As occurred for the antibodies, the induced T-cell responses
measured by IFN-c ELISPOT, not only specifically recognized the
synthetic peptides, but also the pH1N1 virus. Thus, before the
challenge only one out of four of the VIN1-vaccinated pigs showed
detectable T-cell responses in response to in vitro stimulation with
the inactivated pH1N1, while all vaccinated pigs responded at 6
dpi (Fig. 5B).
VIN1 Peptides Induce Antibodies that Recognize Distinct
Viral Subtypes
Current influenza vaccines protect mostly against homologous
virus strains. The presented VIN1-peptide cocktail did not confer
efficient neutralizing antibodies and only one pig did not show
viral RNA in BAL 6 dpi. However, an IF was performed to
demonstrate that vaccination elicits antibodies that recognize
different viruses. VIN1-sera obtained after three immunizations
specifically detected SwH1N1 and H5N1 infected-MDCK cells, as
shown by IF (Fig. 6). Furthermore, antibodies elicited after VIN1-
immunization specifically detected SwH3N2 (Fig. 6).
To further investigate the antibody response, an HI assay was
performed against the same virus subtypes: H5N1 HPAIV,
SwH1N1 IV and SwH3N2 IV. No inhibition activity was
recorded against any of the mentioned virus for any sera.
Discussion
The search for universal vaccines against influenza viruses is a
must. Most efforts have been focussed on driving the immune
response against well conserved epitopes or proteins of IV, such as
the influenza ion channel M2 protein, and conserved
epitopes from the influenza NP and matrix 1 (M1) [12,13,14].
More recently, the potential use of highly conserved synthetic
peptides from HA2 as an efficient vaccine in mice has also been
demonstrated [15]. In this report, we show evidence of the
potential use of conserved HA1 peptides in future vaccine
formulations using conventional pigs.
Table 1. Amino acid sequences from the peptides used for immunization compared to the homologue sequence of the HA
receptor recognition domain of the challenging strain (pH1N1) and the HA purified proteins used for the serologic tests.
Strain Short name Residues Sequence
Challenge
A/Catalonia/63/2009 (H1N1) pH1N1 59–92 SSDNGTCYPGDFIDYEELREQLSSVSSFERFEIF
Immunization
A/South Carolina/1/18 (H1N1) NF-34 87–120 NSENGTCYPGDFIDYEELREQLSSVSSFEKFEIF
A/Egypt/0636-NAMRU3/2007 (H5N1) ES-34 99–132 EELKHLLSRINHFEKIQIIPKNSWSDHEASGVSS
A/Hong Kong/213/03 (H5N1) LE-35.1 41–75 LCDLDGVHPLILRDCSVAGWLLGNPMCDEFINVPE
A/Hong Kong/213/03 (H5N1) LE-35.2 41–75 LCNLDGVKPLILRDCSVAGWLLGNPMCDEFINVPE
HA purified proteins
A/VietNam/1203/04 (H5) VN04 115–149 57–91 EELKHLLSRINHFEKIQIIPKSSWSSHEASLGVSS
LCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPE
A/New Caledonia/20/99 (H1) NCD99 101–134 NPENGTCYPGYFADYEELREQLSSVSSFERFEIF
In bold type, the amionacids differences between sequences are represented. Differences between the pH1N1 virus and the H1-peptide (NF-34) in homologous
positions within the HA receptor recognition domain are marked. Aminoacid differences in the two H5-HK derived peptides (LE-35.1/2) are also represented.
doi:10.1371/journal.pone.0040524.t001
Broad Immune Responses Induced by HA1-peptides
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Peptides derived from the HA1-VIN1 domain were selected by
ISM [6,7] and were used for the immunization carried out in the
present study. As predicted, immunization of pigs with VIN1-
peptides induced specific anti-VIN1 peptides antibodies that
recognized the VIN1-peptides (Fig. 1A and 1B), the H1 and H5
recombinant proteins (Fig. 1C) and also the heterologous pH1N1
IV (Fig. 4). Even though it was not predicted, VIN1-peptide
immunization was also able to induce T-cell responses in every
single conventional pig that, again, not only recognized the specific
peptides but also the heterologous pH1N1 IV. Interestingly
enough, not all peptides seemed to be equally recognized, with
both the NF-34 and ES-34 from the H1 and H5 hemagglutinin,
respectively, being optimally recognized. The fact that these two
epitopes are located in equivalent regions within the primary
structure of the HA1 subunit, validate even more the ISM
predictions.
An ideal vaccine should elicit both humoral and cellular
responses in the context of highly variable Major Histocompat-
ibility Complex (MHC), which is what we found with our vaccine.
The fact that swine and human MHC complexes are remarkably
similar [16], opens avenues for the extrapolation of these and
future results for human medicine.
We observed an increase in virus clearance after the challenge
with pH1N1 virus, which differs in 3 amino acids from NF-34 (the
H1-peptide used in the VIN1-vaccine) (Table 1), in 2 out of 4 of
the immunized pigs. This also opens new expectations for the use
of VIN1-modified peptides in future vaccine formulations. Apart
from sequence diversity, there is a clear lack of correlation between
the protection observed and the immune responses detected at the
individual level. Intriguingly, as soon as at day six post infection,
only 2 pigs (pigs 1 and 2 from the V1N1 peptide-immunized
group) showed concomitant detection of neutralizing and HI
activity that did not totally correlate with protection. While pig 2
showed a clear reduction in viral load, pig 1 showed virus titres
indistinguishable from those found in the control group. Although
disappointing, our results seem to point towards the very
Figure 1. VIN1-peptide cocktail acts as a potent immunogen and the elicited sera reacts with different hemagglutinin subtypes and
against VIN1-peptides. (A) Sera from individuals were obtained 15 days after each immunization and were tested for binding to a mixture of the
VIN1-peptides (serum dilution 1:100) by ELISA. (B) Sera from individual pigs were obtained 15 days after the third immunization and were serially
diluted and tested for binding to each single peptide by ELISA and (C) Sera described in B) were tested for binding to H5- or H1- recombinant
hemagglutinin by ELISA.
doi:10.1371/journal.pone.0040524.g001
Broad Immune Responses Induced by HA1-peptides
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Figure 2. VIN1-HA1 derived peptides immunization induces strong T-cell responses in pigs. (A) Kinetics of the VIN1 peptide-specific T-
cell responses induced 15 days after all immunizations measured by IFNc-ELISPOT. (B) Specific T-cell responses induced 4 weeks after the third
immunization were tested for each single peptide by IFNc-ELISPOT.
doi:10.1371/journal.pone.0040524.g002
Broad Immune Responses Induced by HA1-peptides
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important role of T-cells in the protection afforded which could be
an important tool for developing more efficient vaccines for the
future. Thus, the partial protection observed might correspond
with the induction of non-detectable specific cytotoxic T-cell
activity (CTL), as has been reported before for influenza [17,18] or
with any other kind of T-cell activity independent from the
induction of IFN-c that might be involved in cross-protection [19].
We are currently addressing these issues, including the identifica-
tion of shorter specific CTL-peptides.
The length of the peptides used, as well as the fact that the T-
cells specifically secreted IFN-c in response to in vitro stimulation
with both the NF-34 peptide and the pH1N1 IV, point towards
the induction of specific CD4+-T cells in every single vaccinated
farm pig and independent of its SLA II haplotype. This, together
with the fact that the specific antibodies induced are also able to
recognize the pH1N1 virus, seem to validate the use ISM to
optimize the prediction of highly conserved epitopes with better
protective ability and to design future vaccine formulations,
capable of inducing concomitantly, universal B and T-cell
responses against H1N1 influenza viruses [20].
Unexpectedly, the reduction in the viral loads shown by pigs 2
and 4 did not correlate with less severity in the lung lesions. All
pigs from either control or immunized groups show indistinguish-
able minor hystopathological changes. Despite the fact that these
results could reflect a limitation of our T cell-centric vaccines to
reduce disease, pigs might not be ideal models to test so, mainly
because of the mild disease found after pH1N1 infection. For that
reason, our hypothesis are also being tested in mice and chickens,
which are ideal models for the characterization of the protective
capability of experimental vaccines against an infection with highly
pathogenic H5N1 IV; most probably, the responsible of future
pandemic episodes [21].
Materials and Methods
Ethics Statement
All experiments with the pH1N1 IV were performed at the
Biosafety Level 3 facilities of the Centre de Recerca en Sanitat Animal
(CReSA-Barcelona). Sample from the patient infected by pH1N1
IV was coded prior to isolating the virus to ensure anonymity. For
this reason, the Ethical and Animal Welfare Committee of the
Universitat Auto`noma de Barcelona (UAB) exempted this study from the
requirement to have the consent of the patient, who was infected
with pH1N1 IV. The present study was performed in accordance
with the Guidelines of the Good Experimental Practices and under
the supervision and approvement of the Ethical and Animal
Welfare Committee of the UAB (Permit Number: DMAH-5796).
Animal Experimental Design
A total of eight 8-wk-old conventional crossbreed pigs from a
three-way cross (Duroc x Landrace hybrids paired with Pietrain
boars) seronegative against influenza A virus were immunized
three times two weeks apart. We immunized the pigs with either
15 mg of the VIN1-peptide cocktail (3.5–4 mg of each peptide) or
saline solution in complete Freund’s adjuvant (first immunization),
incomplete Freund’s adjuvant (second dose) and without adjuvant
(last dose), by i.m. administration. Four weeks after the second
boost, the pigs were intranasally inoculated with 106 TCID50 of
the pH1N1 virus. Animals were monitored daily for flu-like clinical
signs. Sera and peripheral blood mononuclear cells (PBMC)
obtained before each immunization, before the challenge and at 6
days post-infection (dpi), were used to detect specific humoral and
cellular responses, respectively. Animals were euthanized at 6 dpi
and a complete necropsy was carried out for each animal.
Bronchoalveolar lavages (BAL) from the right lung of each pig
were performed in 200 ml of PBS 16 immediately after post-
mortem examination. BAL were frozen at 280uC until their use
for viral RNA extraction and quantification. For histopathological
analysis, samples from lung (apical, middle and diaphragmatic
lobes), nasal turbinate and trachea were collected and fixed by
immersion in 10% neutral buffered formalin. In the lung,
broncho-interstitial pneumonia (BIP) intensity was assessed by
means a semi-quantitative scoring (0 to 3, indicating lack of, mild,
moderate or severe pneumonia lesions, respectively), as previously
described [11].
Virus and Purified Hemagglutinins
Viruses used were pH1N1 virus (the pandemic swine-origin A/
Catalonia/63/2009 H1N1 IV) [GenBank GQ464405-GQ464411
and GQ168897], SwH1N1 virus (A/Swine/Spain/003/2010
H1N1 IV) [GenBank JQ319725 and JQ319727], SwH3N2 virus
(A/Swine/Spain/001/2010 H3N2 IV) [GenBank JQ319724 and
JQ319726] and H5N1 HPAI virus (A/great crested grebe/Basque
Country/06.03249/2006 H5N1 HPAIV) [GenBank EU636810
and EU636811]. After propagation at 37uC in the allantoic fluid of
11-day-old embryonated chicken eggs from a specific-pathogen-
free flock, the infectious virus titre was determined in Madin-
Darby Canine Kidney (MDCK, ATCC CCL-34) cells and
measured as tissue culture infectious doses 50% (TCID50) by
following the Reed and Muench method [22]. Purified hemag-
glutinin for A/VietNam/1203/04 (H5) and A/New Caledonia/
20/99 (H1) were purchased from Abcam.
Peptide Synthesis
Four peptides were designed based on ISM predictions [6,7]
and were mixed and used to immunize conventional pigs. The
selected peptides were highly conserved and mapped to the
flanking region of the HA1 within the VIN1 domain. Two
peptides (LE-35.1 and LE-35.2) were derived from A/Hong
Kong/213/03 (H5N1) [GenBank AB212056] and one (ES-34)
from A/Egypt/0636-NAMRU3/2007 (H5N1) [GenBank
EF382359]. The fourth peptide (NF-34) was derived from the
HA1 of the human A/South Carolina/1/18 (H1N1) strain
[GenBank AF117241]. The peptides were produced by GL
Biochem (Shanghai) Ltd. Sequences from the synthetic peptides
(thereafter referred as VIN1-peptides) are shown in Table 1.
Figure 3. Immunization with VIN1-HA1 partially protects pigs
in vivo against heterologous challenge with pH1N1. Influenza
viral RNA quantification in BAL was performed by RT-qPCR at 6 dpi,
corresponding to necropsy day. Bars indicated positive samples in
genome equivalent copies (GEC) per ml of BAL. The detection limit in
the assay was 3 log10 GEC/ml.
doi:10.1371/journal.pone.0040524.g003
Broad Immune Responses Induced by HA1-peptides
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Quantitative Real Time RT-PCR (RT-qPCR)
Viral RNA quantification using TaqMan RT-qPCR was
performed in BAL. Viral RNA was extracted with QIAamp Viral
Mini kit (Qiagen, Inc.). Amplification of a matrix (M) gene
fragment was carried out using primers, probe, one-Step RT-PCR
Master Mix Reagents (Applied Biosystems) and amplification
conditions as described previously by Busquets et al. 2010 [11] in
Fast7500 equipment (Applied Biosystems).
Influenza Nucleoprotein (NP)-specific ELISA
Sera from animals before starting the experiment were
examined for the presence of specific antibodies against influenza
NP using the ID ScreenH Influenza A Antibody Competition
ELISA (ID VET, France), following manufacturer’s instructions.
Pig serum samples were used at 1:100 dilution. Known positive
and negative sera were used as test controls.
Peptide-specific ELISA
A peptide-based ELISA method was developed for the
evaluation of the presence of specific antibodies in serum samples.
Briefly, 96 well plates (Costar, Corning Incorporated) were coated
with 1 mg/ml of each peptide individually, the VIN1-peptides
cocktail or H52/H1- purified hemagglutinin in coating buffer
(sodium bicarbonate 0.1 M) overnight at 4uC. After blocking with
1% casein/PBS 16 for 1-h at 37uC, serum from individuals were
added to the coated plate diluted at 1:100 or titrated with 10-fold
dilutions (starting from 1:10), followed by 2-h incubation at 37uC.
Plates were washed four times with PBS 16/0.1% Tween20 and
anti-pig IgG (whole molecule)-Peroxidase (Sigma) diluted 1:20,000
Figure 4. VIN1-sera recognize pH1N1 virus in vitro. Indirect immunofluorescence of pH1N1-infected MDCK cells at 16 hpi using as primary
antibody: (A) the serum from one pig (representative of the group), immunized three times with VIN1-peptides; (B) the serum from one negative
control pig (representative of the group), immunized three times with PBS; and (C) A monoclonal antibody against the NS-1 protein was used as
control for the infection (right panel).
doi:10.1371/journal.pone.0040524.g004
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was added to wells followed by 45 min incubation at 37uC. After
washing the plates four times (PBS 16/0.1% Tween20), fifty ml of
3,39,5,59-tetramethylbenzidine (TMB) substrate solution were
added to the wells and allowed to develop for 8–10 min at room
temperature (RT) protected from light. Optical density (OD) was
measured at 450 nm.
Haemagglutination Inhibition (HI) Assay
An HI assay was performed following the standard procedures
[23] using chicken red blood cells (RBC) and 4 haemagglutination
units of either pH1N1 IV, SwH1N1 IV, SwH3N2 IV or H5N1
HPAIV. To avoid unspecific inhibitions, sera from individuals
were treated prior to use. Briefly, one volume of serum samples
was treated overnight at 37uC with four volumes of Receptor
Destroying Enzyme (Sigma) solution (100 U/ml). Next day, serum
samples were incubated for 30 min at 56uC after the addition of
five volumes 1.5% sodium citrate. Finally, one volume of a 50%
suspension of RBC was added and incubated for 1-h at 4uC.
Known positive and negative sera were used as controls. HI titres
of $20 were considered positive.
Seroneutralization (SNT) Assay
A SNT assay was done following the protocol described by
Sirskyi and collaborators (2010) [24], with some modifications.
Serum samples were diluted serially and incubated with 100
TCID50 of pH1N1 virus for 2-h at 37uC. The mixture was then
added to 105 MDCK cells/well and incubated overnight. After
two washes with PBS 16, the cells were fixed with cold 80%
acetone for 10 min. Cells were air-dried, washed five times with
PBS 16/0.05% Tween-20 and incubated at RT for 1-h and a half
with biotinylated influenza A anti-NP primary antibody (CAT #
MAB8252B, Millipore, CA) diluted 1/2,000 in 5%FBS/PBS 16.
Plates were then washed five times with PBS 16/0.05% Tween-20
and incubated 30 min in the dark with HRP-conjugate strepta-
vidin (Millipore, CA) diluted 1/10,000 in 5%FBS/PBS 16.
Finally, after five washes with PBS 16/0.05% Tween-20, TMB
substrate (Sigma) was added to develop the reaction and stopped
with Stop-solution H2SO4 (1N). Plates were then read at 450 nm.
IFN-c ELISPOT Assay
An IFN-c ELISPOT was performed as previously described
[25], with some modifications. Briefly, PBMC were isolated from
whole blood by Histopaque-1077 gradient (Sigma). Ninety-six-well
plates (Costar, Corning Incorporated) were coated overnight with
IFNc-capture antibody (P2G10 clon, BD Pharmingen) diluted
1:100. After blocking the plates 1-h at 37uC, 500,000 PBMC/well
were seeded and stimulated with either 2 mg/ml of VIN1-peptide
cocktail or individually, or with 105 TCID50 of inactivated pH1N1
IV per well for 20-h. Cells were removed and a biotin mouse anti-
pig IFN-c detection antibody (BD Pharmingen), diluted 1:1,000,
was used followed by streptavidin-peroxidase (0.5 mg/ml). Insol-
uble TMB blue (Calbiochem) was added as final substrate. Positive
spots were counted using a microscope.
Immunofluorescence Microscopy
MDCK cells (300,000 cells/well) were either mock infected or
infected with pH1N1 IV, SwH1N1 IV, SwH3N2 IV or H5N1
HPAIV for 16-h at a MOI of 0.01. Cells were fixed with 4%
paraformaldehyde and permeabilized with 0.5% Triton X-100.
The cells were then blocked with 3%BSA/PBS 16 for 1-h and
incubated with the sera from the pigs (1:100) for 1-h in the
blocking solution at RT. After three washes with PBS 16, the cells
were incubated with anti-IgG pig:FITC antibody (1:300) (Jackson
Immunoresearch Europe LTd) for 1-h in blocking solution at RT.
Finally, nuclei were counterstained with DAPI (1 mg/ml) and
coverslips were mounted with Vectaschield. Protocol was modified
from the previously described by Ballester et al. 2011 [26].
Fluorescence images were viewed on a Nikon eclipse 90i
epifluorescence microscope equipped with a DXM 1200F camera
(Nikon Corporation, Japan). The images were processed by using
the Image J v1.45l software (http://rsb.info.nih.gov/ij).
Figure 5. Immunization with the VIN1-HA1 peptide induces specific antibodies and T-cells against the heterologous pH1N1 virus.
(A) HI and SNT titers obtained with sera from pigs immunized either with the VIN1-peptides or with saline solution (control), at 6 dpi with the pH1N1
virus. Grey bars represent HI titres and red triangles show SNT. (B) IFNc-ELISPOT using pH1N1 virus as stimulus and PBMCs from pigs immunized
either with the VIN1-peptides or with saline solution (control). The assay was done using PBMCs isolated either before the infection with the
pandemic H1N1 virus or at 6 dpi.
doi:10.1371/journal.pone.0040524.g005
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